Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group

BACKGROUND: Prostate-specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis-diagnosis that would not occur during a man's lifetime without screening-particularly in older men and those with life-limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long-term harms and benefits have not been estimated. METHODS: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50-70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity-adjusted life tables. RESULTS: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI-targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7-3.1 at age 72 years to 4.5-5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6-10.2 at ages 72 to 11.3-12.6 at 76 years. CONCLUSIONS: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life-limiting comorbidities compared with age-matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2026-11-12
DOI
https://doi.org/10.1002/cncr.70620
Citations
1
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
5.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group

Lukas Owens, Louise Christie Walter, Krithika Suresh, Jeremy M. G. Taylor et al.
1 citations
Cancer
Prostate Cancer Diagnosis and Treatment
5.16
article

Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group

Lukas Owens, Louise Christie Walter, Krithika Suresh, Jeremy M. G. Taylor, Roman Gulati, Ruth Etzioni, Alex Tsodikov, Sarah P. Psutka
article en
1 citations

Abstract

BACKGROUND: Prostate-specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis-diagnosis that would not occur during a man's lifetime without screening-particularly in older men and those with life-limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long-term harms and benefits have not been estimated. METHODS: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50-70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity-adjusted life tables. RESULTS: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI-targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7-3.1 at age 72 years to 4.5-5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6-10.2 at ages 72 to 11.3-12.6 at 76 years. CONCLUSIONS: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life-limiting comorbidities compared with age-matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.

CancerVol. 132(22)
University of California, San Francisco (US), University of Washington (US), University of Michigan (US), Fred Hutch Cancer Center (US)
Fred Hutchinson Cancer Research Center, National Institutes of Health, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 11%
Prostate Cancer Diagnosis and Treatment
5.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon